Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups reveals negligible toxicity against three rodent cell-lines

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 4, 2013, Pages 461-464

  Janaszewska, Anna ^a   Ciolkowski, Michal ^a   Wróbel, Dominika ^a   Petersen, Johannes F ^b   Ficker, Mario ^b   Christensen, Jørn B ^b   Bryszewska, Maria ^a   Klajnert, Barbara ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biocompatibility; Mitochondrial membrane potential; PAMAM dendrimer; Reactive oxygen species formation; Surface modification

Indexed keywords

CHINESE HAMSTERS; CYTOTOXIC ACTIVITIES; FOURTH GENERATION; HIPPOCAMPAL CELLS; MITOCHONDRIAL MEMBRANE POTENTIAL; PAMAM DENDRIMER; POLYAMIDOAMINE DENDRIMERS; REACTIVE OXYGEN SPECIES;

BIOCOMPATIBILITY; CELL CULTURE; CELL DEATH; MAGNESIUM PRINTING PLATES; SURFACE TREATMENT; TOXICITY;

DENDRIMERS;

4 CARBOMETHOXYPYRROLIDONE; DENDRIMER; POLYAMIDOAMINE; PYRROLIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL LINE; CYTOTOXICITY; EMBRYO; FIBROBLAST; HAMSTER; HIPPOCAMPUS; LIVER CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NECROSIS; NONHUMAN; RAT; SURFACE PROPERTY;

ANIMALS; CELL LINE; CRICETINAE; CRICETULUS; DENDRIMERS; MICE; PYRROLIDINONES; RATS;

CRICETULUS GRISEUS; RATTUS; RODENTIA;

EID: 84876707812     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.01.010     Document Type: Article

References (19)

1. Svenson S., Tomalia D.A. Dendrimers in biomedical applications - reflections on the field. Adv Drug Deliv Rev 2005, 57:2106-2129.
2. Lembo D., Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother 2010, 21:53-70.
3. Menjoge A.R., Kannan R.M., Tomalia D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 2010, 15:171-185.
4. Mintzer M.A., Grinstaff M.W. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 2011, 40:173-190.
5. Thomas T.P., Huang B., Choi S.K., Silpe J.E., Kotlyar A., Desai A.M., et al. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic. Mol Pharm 2012, 9:2669-2676.
6. Huang B., Kukowska-Latallo J.F., Tang S., Zong H., Johnson K.B., Desai A., et al. The facile synthesis of multifunctional PAMAM dendrimer conjugates through copper-free click chemistry. Bioorg Med Chem Lett 2012, 22:3152-3156.
7. Jain K., Kesharwani P., Gupta U., Jain N.K. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010, 394:122-142.
8. Svenson S., Tomalia D.A. Dendrimers as nanoparticulate drug carriers. Nanoparticulates as drug carriers 2006, 298. Imperial College Press, London. V.P. Torchilin (Ed.).
9. Tomalia DA, Swanson DR, Huang B, inventors; Dendritic Nanotechnologies Ltd. (US), Tomalia DA, Swanson DR, Huang B, assignees. Heterocycle functionalized dendritic polymers. World Patent WO 2004/069878. 19 August 2004.
10. Ciolkowski M., Petersen J.F., Ficker M., Janaszewska A., Christensen J.B., Klajnert B., et al. Surface modification of PAMAM dendrimer improves its biocompatibility. Nanomed NBM 2012, 8:815-817.
11. Aillon K.L., Xie Y., El-Gendy N., Berkland C.J., Forrest M.L. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 2009, 61:457-466.
12. Mukherjee S.V., Byrne H.J. Polyamidoamine dendrimer nanoparticle cytotoxicity, oxidative stress, caspase activation and inflammatory response: experimental observation and numerical simulation. Nanomed NBM 2012, 10.1016/j.nano.2012.05.002.
13. Matylevitch N.P., Schuschereba S.T., Mata J.R., Gilligan G.R., Lawlor D.F., Goodwin C.W., et al. Apoptosis and accidental cell death in cultured human keratinocytes after thermal injury. Am J Pathol 1998, 153:567-577.
14. Karbowski M., Kurono C., Wozniak M., Ostrowski M., Teranishi M., Soji T., et al. Cycloheximide and 4-OH-TEMPO suppress chloramphenicol-induced apoptosis in RL-34 cells via the suppression of the formation of megamitochondria. Biochim Biophys Acta 1999, 1449:25-40.
15. Bucknam J.F., Hernandez H., Kress G.J., Votyakova T.V., Pal S., Reynolds I.J. MitoTracker labeling in primary neuronal and astrocytic cultures: influence of mitochondrial membrane potential and oxidants. J Neurosci Methods 2001, 104:165-176.
16. Inai Y., Yabuki M., Kanno T., Akiyama J., Yasuda T., Utsumi K. Valinomycin induces apoptosis of ascites hepatoma cells (AH-130) in relation to mitochondrial membrane potential. Cell Struct Funct 1997, 22:555-563.
17. Simon H.-U., Haj-Yehia A., Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000, 5:415-418.
18. Herrera B., Alvarez A.M., Sanchez A., Fernandez M., Roncero C., Benito M., et al. Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor (beta) in fetal hepatocytes. FASEB J 2001, 15:741-751.
19. Chauhan A.S., Diwan P.V., Jain N.K., Tomalia D.A. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules 2009, 10:1195-1202.